- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
R&D
Lilly's win in Evista patent case crucial, analyst says
September 24, 2009
Scott OlsonA decision by a federal judge in Indianapolis to turn back a patent challenge to Eli Lilly and Co.'s Evista marks a major
victory for the company, says an analyst who closely follows the pharmaceutical industry.
MoreJudge upholds Lilly's Evista patent
September 24, 2009
J.K. WallA federal judge in Indianapolis turned back a patent challenge to Eli Lilly and Co.’s drug Evista, the company announced
late yesterday.
MoreLilly's Effient launch just one of its many challenges
August 3, 2009
Greg AndrewsEli Lilly and Co. has blasted past analysts’ earnings projections for two straight quarters. But if Lilly officials
take that as a sign they can breathe easier, they need only flip through a stack of Wall Street research reports on the company.
MoreLilly cancels trials for experimental MS drug
July 28, 2009
J.K. WallEli Lilly and Co. and a development partner has canceled clinical trials on an experimental drug to treat multiple sclerosis
after the drug failed to delay progression of the disease in trial patients.
MoreProfessors go online to revolutionize drug discovery
July 20, 2009
IBJ StaffTwo chemistry professors at IUPUI are laboring to create the McDonald’s of research laboratories—low-cost and
all over the world.
MoreWith Byetta's sales stalled, Lilly unveils its own competitor
June 15, 2009
IBJ StaffWhile Eli Lilly and Co. continues to work with a biotech firm on the diabetes medicine Byetta, it's developing a potential
competitor to Byetta all on its own.
MoreBiotechnology firm boosts its protein biz
June 8, 2009
IBJ StaffGreenwood-based Elona Biotechnologies said it has created two subsidiaries to boost its biosimilar/biogeneric/follow-on protein
business.
MoreCommercializing science takes too long, Cook says
May 25, 2009
Taking science from the laboratory to the commercial market takes too much time and is littered with potential pitfalls along
the way.
MoreWith pharma famine looming, Lilly relying on snack-size deals
May 4, 2009
J.K. WallCompared with some of his pharmaceutical CEO peers these days, John Lechleiter has his company on a diet. Instead of using
a mega-merger to bulk up before the famine that patent expirations will bring on the industry next year,
Lechleiter has Eli Lilly and Co. burning management fat while looking for smaller companies to munch on.
MoreIndiana playing trailblazing role in drive to tailor pharmaceuticals to genetic makeup of individuals
April 13, 2009
Chris O'MalleyIndiana is becoming not only a hotbed of "pharmacogenomics" research, but also a trailblazer in finding practical ways to
use it on the practitioner level.
MoreBiotech push may help offset generic competition; some analysts skeptical
February 2, 2009
J.K. WallLilly executives want to make biotech their top focus.
MoreLilly taps hedge fund to cut research costs for Alzheimer's drugs
August 11, 2008
J.K. WallEli Lilly and Co.'s unorthodox efforts to develop new treatments for Alzheimer's disease--if successful--could usher in a new approach to drug development. The Indianapolis-based pharmaceutical company announced that a New York hedge fund, TPG-Axon Capital, will invest up to $325 million to help cover the exorbitant development costs of two experimental compounds to treat Alzheimer's disease.
Lilly under gun to replace aging blockbuster Zyprexa
November 5, 2007
J.K. WallThere's a $2 billion hole in Eli Lilly and Co.'s future. That's roughly how much pretax profit Lilly derives each year from
its best-seller, Zyprexa, according to calculations by IBJ. And it's how much black ink will start running off Lilly's books
once Zyprexa's U.S. and European patents expire in 2011.
MoreLilly still breathing in inhaler pursuit
April 2, 2007
J.K. WallPfizer Inc.'s new inhaled insulin product, Exubera, has stumbled out of the gate. That would appear to keep the door open
for Eli Lilly and Co., as well as for other companies racing to develop inhaled insulin. But Pfizer's troubles might cause
doctors and patients to sour on all inhaled insulin products.
MoreLilly decides to self-insure for product liability
September 4, 2006
Tom MurphyEli Lilly and Co. has picked an insurer it knows extremely well to cover future problems in the high-stakes world of product
liability litigation--itself. The Indianapolis drugmaker opted for self-insurance after struggling to find coverage in what
it terms a "very restrictive insurance market."
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Laura-the festivals and tastings are free. What does is strengthen the sense of community with activities. What are those empty lots doing for the Village? it's sad you can't see the good that this progress can do for the area. No one is requiring anyone to shop there. I guess you'd rather see a Dollar store move in or no, we'd rather see the property stand empty b/c change is out of the question.
Read down to the part about Brizzi. Someone needs to subpoena his "purchases" of Red RockPictures and Cellstar and his corresponding bank records, I mean c'mon, I'd like to see his alcohol usage records, too. http://diana-vice.blogspot.com/2011_01_01_archive.html
Wonder if my neighborhood can advertise our "retention" pond and act like it is a beach too?
a new record at the '11 salebration until they realized that it was a futile effort to get their crapwagon moter and crapwagon car up speed. And then they just quietly slunk off into the night and never spoke of it again. Nothing to see here folks.
millions for putting a company's bumper sticker on one of its Lolas. But you gotta take what you can get.